The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death of a young man who died following treatment.

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Highlighted with 90 tables and 69 figures, this 168-page report ?Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic ...

Ex-Intel head says TSMC’s new investment will not resurrect US chip sector Read the Market Summary Here:- Highlighted with 142 tables and 105 figures, this 228-page report ?Global Pharmaceutical ...

Company announcement - No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078) ...

The biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...